Mounjaro weekly weight loss claims: what the data actually shows

What did @katiewebberxx actually say?

Honestly? Not much, at least not verbally. The transcript is entirely song lyrics, not commentary about Mounjaro, PCOS, or weight loss. The actual claims in this video appear to be delivered visually, likely through text overlays or on-screen weight figures showing weekly losses, with a discount code in the bio pointing to a Mounjaro-adjacent product or service.

This matters because we can only fact-check what was said or shown. Based on the caption referencing "how much I've lost per week" on Mounjaro 5mg, the implicit claim is that the weight figures displayed reflect typical or expected results on tirzepatide. That framing, a before/after weekly weigh-in series, carries its own set of assumptions worth unpacking.

Does the science back up typical Mounjaro weight loss claims?

Tirzepatide does produce meaningful weight loss, and the evidence for that is actually pretty strong. But the word "typical" is doing a lot of work here, and individual weekly results can be wildly misleading as a benchmark.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed that adults with obesity on tirzepatide 15mg lost an average of 20.9% of body weight over 72 weeks. At 5mg, the same trial showed approximately 15% body weight reduction. Those are averages across a controlled population, not what any individual week looks like. Week-to-week variation is expected and often dramatic. Water retention, hormonal cycles, and caloric variation can all shift the scale by 1 to 3 pounds in either direction with no change in fat mass.

For someone with PCOS specifically, as indicated in the hashtags, there is emerging evidence that GLP-1/GIP dual agonists like tirzepatide may improve insulin resistance markers that contribute to weight gain in this population. A 2023 study (Fruzzetti et al., Journal of Clinical Endocrinology and Metabolism) found tirzepatide improved metabolic parameters in women with PCOS, though sample sizes were small. The mechanism makes biological sense. The magnitude of benefit in real-world PCOS patients is still being quantified.

What did they get wrong, or right?

Without seeing the actual on-screen numbers, a definitive verdict is not possible. But the format itself is the problem. Weekly weigh-in series presented alongside discount codes create an incentive structure that rewards dramatic drops, not honest averages. There is no wrong number shown here, but the selection of which weeks to include, and how they are framed, shapes viewer expectations significantly.

What they appear to get right: documenting real-world results on Mounjaro 5mg in a PCOS context has genuine value, since clinical trials typically underrepresent this population. Personal tracking, including calorie counting as referenced in the hashtags, is consistent with evidence-based weight management approaches used alongside GLP-1 therapy.

What is potentially misleading: the discount code in the bio. If that code links to a compounded tirzepatide product, viewers should know that compounded drugs are not FDA-approved and are not equivalent to brand-name Mounjaro. The FDA has specifically flagged risks associated with compounded tirzepatide. That is not a technicality. That is a patient safety issue.

What should you actually know?

If you are watching weekly weigh-in videos and calibrating your expectations based on them, you are setting yourself up for disappointment or, worse, assuming something is wrong with your response when you hit a slow week.

Average weekly weight loss on tirzepatide in the SURMOUNT trials worked out to roughly 0.2 to 0.5 pounds per week across the full treatment period, with faster loss early and slowdown after several months. Anyone showing 2 to 3 pounds per week consistently over many weeks is either in early treatment, in a significant caloric deficit, or showing you a curated slice of their data.

Mounjaro is a prescription medication approved for type 2 diabetes in the UK and EU, and for weight management as Zepbound in the US. It is not suitable for everyone, and decisions about starting, adjusting, or stopping it should happen with a prescribing clinician, not based on a TikTok comment section. Side effects including nausea, vomiting, and gastrointestinal distress are common, particularly during dose escalation.

• Weekly scale weight is not the same as weekly fat loss.
• PCOS affects how and when weight loss occurs, including due to fluid shifts tied to hormonal changes.
• A discount code for any medication-adjacent product warrants scrutiny about what exactly is being sold.